NG-nitro-L-arginine

NG-nitro-L-arginine (Nω-nitro-L-arginine) is a NO Synthase inhibitor, with Kis of 0.61 μM (nNOS), 4.28 μM (iNOS), 0.72 μM (eNOS) respectively. NG-nitro-L-arginine inhibits endothelium-derived relaxing factor (EDRF) formation and release. NG-nitro-L-arginine inhibits portal-systemic shunting in portal-hypertensive rats, and increases blood pressure[1][2][3][4].

Product Specifications

CAS Number

[2149-70-4]

Product Name Alternative

Nω-nitro-L-arginine; L-NOARG; L-NG-Nitroarginine

UNSPSC

12352211

Hazard Statement

H228, H315, H319

Target

NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ng-nitro-l-arginine.html

Purity

99.78

Solubility

1 M HCl : 100 mg/mL (ultrasonic)

Smiles

N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(O)=O

Molecular Formula

C6H13N5O4

Molecular Weight

219.20

Precautions

H228, H315, H319

References & Citations

[1]Seo J, et al. Structure-based design and synthesis of N (omega) -nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. J Med Chem. 2007 May 3;50 (9) :2089-99. |[2]Ishii K, et al. N omega-nitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol. 1990 Feb 6;176 (2) :219-23. |[3]Lee FY, et al. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 1993 Nov;105 (5) :1464-70.|[4]Molnár M, Hertelendy F. N omega-nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am J Obstet Gynecol. 1992 May;166 (5) :1560-7.